InteKrin Raises $23 Million

InteKrin Therapeutics Inc., a Palo Alto, Calif.-based drug company focused on metabolic disorders, has raised $23 million in second-round funding. Sofinnova Ventures led the deal, and was joined by Orbimed Advisors, Vivo Ventures and return backers Asset Management and Sears Capital Management.